Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX
BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell” or the “Company”)…
Multiple Paths Can Lead to Cybersecurity Success
Instruct3D Strengthens Additive Build Intelligence Message Following ICAM 2026
Otto Group and Sereact Bring NVIDIA-Powered Physical AI to Returns Processing